Vaccinex Inc - Ordinary Shares

Vaccinex Inc. a clinical-stage biotechnology company engages in the discovery and development of targeted biotherapeutics to treat cancer neurodegenerative diseases and autoimmune disorders. The company's lead drug candidate pepinemab a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed ActivMAb an antibody drug discovery platform based on a novel method for complex targets such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester New York.